ZDA
EW icon

Zweig-DiMenna Associates’s Edwards Lifesciences EW Stock Holding History

Zweig-DiMenna Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,400
Closed -$242K – 299
2014
Q4 		$242K Buy
+11,400
New +$229K 0.01% 240

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Zweig-DiMenna Associates's EW Position: Q1 2015 in Review

Zweig-DiMenna Associates sold out of Edwards Lifesciences (EW) in Q1 2015, closing a stake of 11,400 shares — an estimated $242K sold.

Zweig-DiMenna Associates first reported a position in EW in Q4 2014 and held it in 1 quarter. The position peaked at $242K in Q4 2014. 575 funds tracked by Wall St. Rank hold EW as of Q1 2015.

  • Zweig-DiMenna Associates reported no remaining Edwards Lifesciences position as of Q1 2015 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 11,400 Edwards Lifesciences shares in Q1 2015, an estimated $242K.
  • Zweig-DiMenna Associates first reported a position in Edwards Lifesciences in Q4 2014 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Edwards Lifesciences position peaked at $242K in Q4 2014.
  • 575 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2015, filed 11 May 2015.